Sanofi launches five P3 clinical trials for Hanmi’s diabetic drug

Hanmi Pharmaceutical said Friday that Sanofi, its global partner for efpeglenatide, a new diabetes drug candidate, has managed to add two more phase 3 trials. With the two new trials, there are now 6,400 patients participating in five types of research g http://www.koreabiomed.com/news/articleView.html